

Reduced Oxygen Packaging (ROP) Committee Recommendations

1. The ISSC Executive Board identify funding for studies to determine the following:
 - a. Are the present shucking and packing practices providing controls that can explain why there are no reported cases of illness associated with C. Botulinum?
 - b. Determine the effect that normal product deterioration has on PH. Determine if PH reaches a level that prohibits C. Botulinum growth.
 - c. Determine if a reduced shelf life offers a potential C. Botulinum control.
 - d. Conduct a study of competitive bacteria and its effect on C. Botulinum growth.

Approved to prioritize Items a. through d.; present recommendations to FDA and seek advice on costs to conduct studies; and report results to Executive Board.

2. The ISSC Executive Board requested that FDA conduct a cost analysis of the impact of Proposal 15-208.

Approved

3. The ISSC Executive Board requested that FDA determine how packaging changes would affect exports.

Approved

4. The ISSC Executive Board requested that FDA consult with other countries to determine what other countries are doing to address C. Botulinum in shucked shellfish.

Approved

5. The ISSC Executive Board requested that FDA provide the rationale for the Agency's determination that C. Botulinum is reasonably likely to cause illness associated with consumption of shucked shellfish.

Approved